Dopamine D2 and D3 receptor occupancy evaluation study of antipsychotics by positron emission tomography

Dopamine D2 and D3 receptor occupancy evaluation study of antipsychotics by positron emission tomography - Dopamine D2 and D3 receptor occupancy evaluation study of antipsychotics

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021166

Enrollment

Registered

2016-03-01

Start date

2016-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

1)PET, MRI, blood concentration 2)blonanserin 12mg, PET, MRI, blood concentration 3)olanzapine 10mg, PET, MRI, blood concentration 1)PET, MRI, blood concentration 2)olanzapine 10mg, PET, MRI, blood

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Subjects who have the ability to provide informed consent and adhere to the protocol. Subjects without previous history of illness and/or injury that influences the psychiatric illness and/or central nervous system. Subjects without taking the medicine that influences the cognitive functions. Subjects without the history of smoking.

Exclusion criteria

Exclusion criteria: Exclusion criteria: - with past or current history of psychiatric illness - with past or current history of serious medical illness and/or brain organic diseases - subject who is contraindicated for the use of MRI - with past or current history ofsevere liver disease, kidney disease, heart disease, allergy, or severe drug allergy - subject who are judged as not suitable for participation in this study

Design outcomes

Primary

Measure	Time frame
To investigate the characteristics of antipsychotics by evaluating the dopamine D2 and D3 receptor occupancy of antipsychotics before and after taking single dose of medicine.	—

Secondary

Measure	Time frame
blood concentration, MRI, neuropsychological test	—

Countries

Japan

Contacts

Public ContactAmane Tateno

Nippon Medical School Department of Neuropsychiatry

amtateno@nms.ac.jp+81-3-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026